Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Common Equity (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Common Equity for 5 consecutive years, with $29.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 66.87% to $29.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $29.6 million, a 66.87% decrease, with the full-year FY2024 number at $73.4 million, down 34.1% from a year prior.
  • Common Equity was $29.6 million for Q3 2025 at Werewolf Therapeutics, down from $41.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $181.6 million in Q2 2021 to a low of -$153.8 million in Q1 2021.
  • A 5-year average of $97.3 million and a median of $117.6 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 190.61% in 2022, then crashed 66.87% in 2025.
  • Werewolf Therapeutics' Common Equity stood at $152.8 million in 2021, then decreased by 19.93% to $122.3 million in 2022, then dropped by 8.96% to $111.4 million in 2023, then tumbled by 34.1% to $73.4 million in 2024, then crashed by 59.65% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Common Equity are $29.6 million (Q3 2025), $41.5 million (Q2 2025), and $57.3 million (Q1 2025).